Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Market watch: Innovation in the preclinical antibiotic pipeline.
Theuretzbacher U, Savic M, Årdal C, Outterson K. Theuretzbacher U, et al. Nat Rev Drug Discov. 2017 Nov;16(11):744-745. doi: 10.1038/nrd.2017.195. Epub 2017 Oct 6. Nat Rev Drug Discov. 2017. PMID: 28983100 No abstract available.
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Tacconelli E, et al. Among authors: theuretzbacher u. Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21. Lancet Infect Dis. 2018. PMID: 29276051
The global preclinical antibacterial pipeline.
Theuretzbacher U, Outterson K, Engel A, Karlén A. Theuretzbacher U, et al. Nat Rev Microbiol. 2020 May;18(5):275-285. doi: 10.1038/s41579-019-0288-0. Epub 2019 Nov 19. Nat Rev Microbiol. 2020. PMID: 31745331 Free PMC article. Review.
Challenges and shortcomings of antibacterial discovery projects.
Theuretzbacher U, Baraldi E, Ciabuschi F, Callegari S. Theuretzbacher U, et al. Clin Microbiol Infect. 2023 May;29(5):610-615. doi: 10.1016/j.cmi.2022.11.027. Epub 2022 Dec 8. Clin Microbiol Infect. 2023. PMID: 36503116 Free PMC article.
Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation.
Årdal C, Baraldi E, Busse R, Castro R, Ciabuschi F, Cisneros JM, Gyssens IC, Harbarth S, Kostyanev T, Lacotte Y, Magrini N, McDonnell A, Monnier AA, Moon S, Mossialos E, Peñalva G, Ploy MC, Radulović M, Ruiz AA, Røttingen JA, Sharland M, Tacconelli E, Theuretzbacher U, Vogler S, Sönksen UW, Åkerfeldt K, Cars O, O'Neill J. Årdal C, et al. Among authors: theuretzbacher u. Lancet. 2024 Jan 13;403(10422):e2-e4. doi: 10.1016/S0140-6736(23)00282-9. Epub 2023 Feb 9. Lancet. 2024. PMID: 36774936 No abstract available.
Antibiotic research and development: business as usual?
Harbarth S, Theuretzbacher U, Hackett J; DRIVE-AB consortium. Harbarth S, et al. Among authors: theuretzbacher u. J Antimicrob Chemother. 2015;70(6):1604-7. doi: 10.1093/jac/dkv020. Epub 2015 Feb 10. J Antimicrob Chemother. 2015. PMID: 25673635
Antibiotic innovation for future public health needs.
Theuretzbacher U. Theuretzbacher U. Clin Microbiol Infect. 2017 Oct;23(10):713-717. doi: 10.1016/j.cmi.2017.06.020. Epub 2017 Jun 24. Clin Microbiol Infect. 2017. PMID: 28652114 Free article. Review.
75 results